---
title: "JoynCare drops over 10% amid CRO sector weakness"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292986397.md"
description: "JoynCare (6127.HK) fell more than 10% to HK$23.42 during trading as the CRO sector weakened."
datetime: "2026-07-17T05:10:28.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292986397.md)
  - [en](https://longbridge.com/en/news/292986397.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292986397.md)
generator: "portal-rs"
---

# JoynCare drops over 10% amid CRO sector weakness

JoynCare (6127.HK) tumbled more than 10% to **HK$23.42** during regular trading.

The decline came as Hong Kong pharmaceutical stocks slid broadly, with CRO concepts leading losses. WuXi AppTec dropped over 8% and Pharmaron declined more than 7%, dragging sentiment across the sector.

### Related Stocks

- [06127.HK](https://longbridge.com/en/quote/06127.HK.md)

## Related News & Research

- [Akeso says Phase III HARMONi-2 trial shows ivonescimab lifts overall survival vs pembrolizumab in PD-L1-positive NSCLC](https://longbridge.com/en/news/298823675.md)
- [Comba Telecom Systems posts 2026 interim report online](https://longbridge.com/en/news/298711905.md)
- [Shanghai Henlius says China regulator accepts NDA for 120 mg denosumab biosimilar HLX14](https://longbridge.com/en/news/298701598.md)
- [Lee’s Pharm signs exclusive OC-3 cancer drug licensing deal with 1cBio for China, Hong Kong, Taiwan, Southeast Asia markets](https://longbridge.com/en/news/298473298.md)
- [SystImmune, Inc. to Present New Global Data on Iza-bren (izalontamab brengitecan) in EGFR-mutated Non-Small Cell Lung Cancer at WCLC Congress 2026](https://longbridge.com/en/news/298803564.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**